ParkinsonFranceV1, PascalFrancis, Curation, bibRecord, 001772

Apomorphine in patients with Parkinson's disease : Parkinson's disease

Identifieur interne : 001772 ( PascalFrancis/Curation ); précédent : 001771; suivant : 001773

Apomorphine in patients with Parkinson's disease : Parkinson's disease

Auteurs : D. Muguet [France] ; E. Broussolle ; G. Chazot

Source :

Biomedicine & pharmacotherapy [ 0753-3322 ] ; 1995.

RBID : Pascal:95-0405164

Descripteurs français

Pascal (Inist)
- Apomorphine, Stimulant dopaminergique, Parkinson maladie, Récepteur dopaminergique, Agoniste, Chimiothérapie, Traitement, Homme.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Agonist, Chemotherapy, Dopamine agonist, Dopamine receptor, Human, Parkinson disease, Treatment.

Abstract

We present a review of the recent literature and personal experience with apomorphine in patients with Parkinson's disease. Apomorphine is a potent D₁ and D₂ dopaminergic agonist. It has a rapid and short duration effect after subcutaneous administration at doses ranging from 15 to 180 μg/kg. Plasma maximal concentration is reached in 8-16 minutes, with a plasma half life of 34-70 minutes. Bioavailability is close to 100%. Repeated injections in patients show post-stimulative hyposensitivity. Apomorphine test appears very useful for the differential diagnosis between idiopathic Parkinson's disease and other Parkinson plus syndromes, and as a predictive test for dopaminergic responsiveness. Appropriate doses arc able to alleviate akinesia, rigidity and tremor. Recent therapeutic trials have demonstrated the high interest of intermittent multiple subcutaneous apomorphine injections to cut the "off" motor phases in fluctuating parkinsonian patients under chronic levodopa treatment. In some cases. continuous apomorphine subcutaneous infusion with a portable pump may be required, particularly when levodopa treatment is temporarily interrupted, as after abdominal sugery. During long-term treatment, the apomorphine dose able to relieve akinesia remains stable. Peripheral side effects such as nausea and hypotension may be prevented by the co-administration of domperidone. a peripheral dopaminergic antagonist. Cutaneous fibrous nodules and psychiatric symptoms may occur, but usually at high dosages with continuous infusion. Local allergic effects have limited the use of other routes of administration, such as intranasal, sublingual. and rectal routes. Apomorphine is also used as a pharmacological tool for clinical research with the aim of better understanding of the pathophysiology of Parkinson's disease.

A01	`01`	`1`		`@0 0753-3322`
A02	`01`			`@0 BIPHEX`
A03		`1`		`@0 Biomed. pharmacother.`
A05				`@2 49`
A06				`@2 4`
A08	`01`	`1`	`ENG`	`@1 Apomorphine in patients with Parkinson's disease : Parkinson's disease`
A11	`01`	`1`		`@1 MUGUET (D.)`
A11	`02`	`1`		`@1 BROUSSOLLE (E.)`
A11	`03`	`1`		`@1 CHAZOT (G.)`
A14	`01`			`@1 Hôp. neurologique neurochirurgical Pierre Wertheimer, serv. neurologie C @2 69003 Lyon @3 FRA`
A20				`@1 197-209`
A21				`@1 1995`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 4790 @5 354000051591740050`
A44				`@0 0000`
A45				`@0 103 ref.`
A47	`01`	`1`		`@0 95-0405164`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Biomedicine & pharmacotherapy`
A66	`01`			`@0 FRA`
C01	`01`		`ENG`	@0 We present a review of the recent literature and personal experience with apomorphine in patients with Parkinson's disease. Apomorphine is a potent D₁ and D₂ dopaminergic agonist. It has a rapid and short duration effect after subcutaneous administration at doses ranging from 15 to 180 μg/kg. Plasma maximal concentration is reached in 8-16 minutes, with a plasma half life of 34-70 minutes. Bioavailability is close to 100%. Repeated injections in patients show post-stimulative hyposensitivity. Apomorphine test appears very useful for the differential diagnosis between idiopathic Parkinson's disease and other Parkinson plus syndromes, and as a predictive test for dopaminergic responsiveness. Appropriate doses arc able to alleviate akinesia, rigidity and tremor. Recent therapeutic trials have demonstrated the high interest of intermittent multiple subcutaneous apomorphine injections to cut the "off" motor phases in fluctuating parkinsonian patients under chronic levodopa treatment. In some cases. continuous apomorphine subcutaneous infusion with a portable pump may be required, particularly when levodopa treatment is temporarily interrupted, as after abdominal sugery. During long-term treatment, the apomorphine dose able to relieve akinesia remains stable. Peripheral side effects such as nausea and hypotension may be prevented by the co-administration of domperidone. a peripheral dopaminergic antagonist. Cutaneous fibrous nodules and psychiatric symptoms may occur, but usually at high dosages with continuous infusion. Local allergic effects have limited the use of other routes of administration, such as intranasal, sublingual. and rectal routes. Apomorphine is also used as a pharmacological tool for clinical research with the aim of better understanding of the pathophysiology of Parkinson's disease.
C02	`01`	`X`		`@0 002B02B06`
C03	`01`	`X`	`FRE`	`@0 Apomorphine @2 NK @2 FR @5 01`
C03	`02`	`X`	`FRE`	`@0 Stimulant dopaminergique @5 04`
C03	`02`	`X`	`ENG`	`@0 Dopamine agonist @5 04`
C03	`02`	`X`	`SPA`	`@0 Estimulante dopaminérgico @5 04`
C03	`03`	`X`	`FRE`	`@0 Parkinson maladie @5 10`
C03	`03`	`X`	`ENG`	`@0 Parkinson disease @5 10`
C03	`03`	`X`	`SPA`	`@0 Parkinson enfermedad @5 10`
C03	`04`	`X`	`FRE`	`@0 Récepteur dopaminergique @5 16`
C03	`04`	`X`	`ENG`	`@0 Dopamine receptor @5 16`
C03	`04`	`X`	`SPA`	`@0 Receptor dopaminérgico @5 16`
C03	`05`	`X`	`FRE`	`@0 Agoniste @5 17`
C03	`05`	`X`	`ENG`	`@0 Agonist @5 17`
C03	`05`	`X`	`SPA`	`@0 Agonista @5 17`
C03	`06`	`X`	`FRE`	`@0 Chimiothérapie @5 18`
C03	`06`	`X`	`ENG`	`@0 Chemotherapy @5 18`
C03	`06`	`X`	`SPA`	`@0 Quimioterapia @5 18`
C03	`07`	`X`	`FRE`	`@0 Traitement @5 19`
C03	`07`	`X`	`ENG`	`@0 Treatment @5 19`
C03	`07`	`X`	`GER`	`@0 Aufbereiten @5 19`
C03	`07`	`X`	`SPA`	`@0 Tratamiento @5 19`
C03	`08`	`X`	`FRE`	`@0 Homme @5 20`
C03	`08`	`X`	`ENG`	`@0 Human @5 20`
C03	`08`	`X`	`SPA`	`@0 Hombre @5 20`
C07	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 61`
C07	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 61`
C07	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 61`
C07	`02`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 62`
C07	`02`	`X`	`ENG`	`@0 Central nervous system disease @5 62`
C07	`02`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 62`
C07	`03`	`X`	`FRE`	`@0 Encéphale pathologie @5 63`
C07	`03`	`X`	`ENG`	`@0 Cerebral disorder @5 63`
C07	`03`	`X`	`SPA`	`@0 Encéfalo patología @5 63`
C07	`04`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 64`
C07	`04`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 64`
C07	`04`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 64`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 65`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 65`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 65`
N21				`@1 225`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001875

Links to Exploration step

Pascal:95-0405164

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Apomorphine in patients with Parkinson's disease : Parkinson's disease</title>
<author><name sortKey="Muguet, D" sort="Muguet, D" uniqKey="Muguet D" first="D." last="Muguet">D. Muguet</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Hôp. neurologique neurochirurgical Pierre Wertheimer, serv. neurologie C</s1>
<s2>69003 Lyon</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Broussolle, E" sort="Broussolle, E" uniqKey="Broussolle E" first="E." last="Broussolle">E. Broussolle</name>
</author>
<author><name sortKey="Chazot, G" sort="Chazot, G" uniqKey="Chazot G" first="G." last="Chazot">G. Chazot</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">95-0405164</idno>
<date when="1995">1995</date>
<idno type="stanalyst">PASCAL 95-0405164 INIST</idno>
<idno type="RBID">Pascal:95-0405164</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001875</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001772</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Apomorphine in patients with Parkinson's disease : Parkinson's disease</title>
<author><name sortKey="Muguet, D" sort="Muguet, D" uniqKey="Muguet D" first="D." last="Muguet">D. Muguet</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Hôp. neurologique neurochirurgical Pierre Wertheimer, serv. neurologie C</s1>
<s2>69003 Lyon</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Broussolle, E" sort="Broussolle, E" uniqKey="Broussolle E" first="E." last="Broussolle">E. Broussolle</name>
</author>
<author><name sortKey="Chazot, G" sort="Chazot, G" uniqKey="Chazot G" first="G." last="Chazot">G. Chazot</name>
</author>
</analytic>
<series><title level="j" type="main">Biomedicine & pharmacotherapy</title>
<title level="j" type="abbreviated">Biomed. pharmacother.</title>
<idno type="ISSN">0753-3322</idno>
<imprint><date when="1995">1995</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Biomedicine & pharmacotherapy</title>
<title level="j" type="abbreviated">Biomed. pharmacother.</title>
<idno type="ISSN">0753-3322</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Agonist</term>
<term>Chemotherapy</term>
<term>Dopamine agonist</term>
<term>Dopamine receptor</term>
<term>Human</term>
<term>Parkinson disease</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Apomorphine</term>
<term>Stimulant dopaminergique</term>
<term>Parkinson maladie</term>
<term>Récepteur dopaminergique</term>
<term>Agoniste</term>
<term>Chimiothérapie</term>
<term>Traitement</term>
<term>Homme</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We present a review of the recent literature and personal experience with apomorphine in patients with Parkinson's disease. Apomorphine is a potent D<sub>1</sub>
 and D<sub>2</sub>
 dopaminergic agonist. It has a rapid and short duration effect after subcutaneous administration at doses ranging from 15 to 180 μg/kg. Plasma maximal concentration is reached in 8-16 minutes, with a plasma half life of 34-70 minutes. Bioavailability is close to 100%. Repeated injections in patients show post-stimulative hyposensitivity. Apomorphine test appears very useful for the differential diagnosis between idiopathic Parkinson's disease and other Parkinson plus syndromes, and as a predictive test for dopaminergic responsiveness. Appropriate doses arc able to alleviate akinesia, rigidity and tremor. Recent therapeutic trials have demonstrated the high interest of intermittent multiple subcutaneous apomorphine injections to cut the "off" motor phases in fluctuating parkinsonian patients under chronic levodopa treatment. In some cases. continuous apomorphine subcutaneous infusion with a portable pump may be required, particularly when levodopa treatment is temporarily interrupted, as after abdominal sugery. During long-term treatment, the apomorphine dose able to relieve akinesia remains stable. Peripheral side effects such as nausea and hypotension may be prevented by the co-administration of domperidone. a peripheral dopaminergic antagonist. Cutaneous fibrous nodules and psychiatric symptoms may occur, but usually at high dosages with continuous infusion. Local allergic effects have limited the use of other routes of administration, such as intranasal, sublingual. and rectal routes. Apomorphine is also used as a pharmacological tool for clinical research with the aim of better understanding of the pathophysiology of Parkinson's disease.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0753-3322</s0>
</fA01>
<fA02 i1="01"><s0>BIPHEX</s0>
</fA02>
<fA03 i2="1"><s0>Biomed. pharmacother.</s0>
</fA03>
<fA05><s2>49</s2>
</fA05>
<fA06><s2>4</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Apomorphine in patients with Parkinson's disease : Parkinson's disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>MUGUET (D.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>BROUSSOLLE (E.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>CHAZOT (G.)</s1>
</fA11>
<fA14 i1="01"><s1>Hôp. neurologique neurochirurgical Pierre Wertheimer, serv. neurologie C</s1>
<s2>69003 Lyon</s2>
<s3>FRA</s3>
</fA14>
<fA20><s1>197-209</s1>
</fA20>
<fA21><s1>1995</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>4790</s2>
<s5>354000051591740050</s5>
</fA43>
<fA44><s0>0000</s0>
</fA44>
<fA45><s0>103 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>95-0405164</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Biomedicine & pharmacotherapy</s0>
</fA64>
<fA66 i1="01"><s0>FRA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>We present a review of the recent literature and personal experience with apomorphine in patients with Parkinson's disease. Apomorphine is a potent D<sub>1</sub>
 and D<sub>2</sub>
 dopaminergic agonist. It has a rapid and short duration effect after subcutaneous administration at doses ranging from 15 to 180 μg/kg. Plasma maximal concentration is reached in 8-16 minutes, with a plasma half life of 34-70 minutes. Bioavailability is close to 100%. Repeated injections in patients show post-stimulative hyposensitivity. Apomorphine test appears very useful for the differential diagnosis between idiopathic Parkinson's disease and other Parkinson plus syndromes, and as a predictive test for dopaminergic responsiveness. Appropriate doses arc able to alleviate akinesia, rigidity and tremor. Recent therapeutic trials have demonstrated the high interest of intermittent multiple subcutaneous apomorphine injections to cut the "off" motor phases in fluctuating parkinsonian patients under chronic levodopa treatment. In some cases. continuous apomorphine subcutaneous infusion with a portable pump may be required, particularly when levodopa treatment is temporarily interrupted, as after abdominal sugery. During long-term treatment, the apomorphine dose able to relieve akinesia remains stable. Peripheral side effects such as nausea and hypotension may be prevented by the co-administration of domperidone. a peripheral dopaminergic antagonist. Cutaneous fibrous nodules and psychiatric symptoms may occur, but usually at high dosages with continuous infusion. Local allergic effects have limited the use of other routes of administration, such as intranasal, sublingual. and rectal routes. Apomorphine is also used as a pharmacological tool for clinical research with the aim of better understanding of the pathophysiology of Parkinson's disease.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Apomorphine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Stimulant dopaminergique</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Dopamine agonist</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Estimulante dopaminérgico</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>10</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>10</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Récepteur dopaminergique</s0>
<s5>16</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Dopamine receptor</s0>
<s5>16</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Receptor dopaminérgico</s0>
<s5>16</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Agoniste</s0>
<s5>17</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Agonist</s0>
<s5>17</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Agonista</s0>
<s5>17</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>18</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>18</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>18</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Traitement</s0>
<s5>19</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Treatment</s0>
<s5>19</s5>
</fC03>
<fC03 i1="07" i2="X" l="GER"><s0>Aufbereiten</s0>
<s5>19</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>19</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>61</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>61</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>61</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>62</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>62</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>62</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>63</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>63</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>63</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>64</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>64</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>64</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>65</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>65</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>65</s5>
</fC07>
<fN21><s1>225</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001772 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 001772 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:95-0405164
   |texte=   Apomorphine in patients with Parkinson's disease : Parkinson's disease
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Apomorphine in patients with Parkinson's disease : Parkinson's disease

Apomorphine in patients with Parkinson's disease : Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri